FDA greenlights digital fix for lazy eye as safer device
Published Date: 4/22/2026
Rule
Summary
The FDA is officially classifying the digital therapy device for amblyopia (lazy eye) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool, innovative treatment faster and safer. The new classification is effective April 22, 2026, but it’s been in effect since October 20, 2021, so manufacturers can plan ahead without surprise costs or delays.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Class II makes amblyopia therapy more available
The FDA officially classified the digital therapy device for amblyopia as Class II (special controls), effective April 22, 2026, with the classification applicable on October 20, 2021. You (patients with amblyopia) may get faster and safer access to this digital treatment because the device faces lower regulatory hurdles than automatic Class III assignment.
De Novo decision creates a predicate device
Because FDA granted De Novo classification for this device (order issued October 20, 2021), the device can serve as a predicate for future substantially equivalent devices. Device sponsors can use the less-burdensome 510(k) route for future devices of this type instead of submitting additional De Novo requests or premarket approval applications.
Device remains subject to 510(k) premarket notification
The digital therapy device for amblyopia is subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless and until FDA determines the device type should be exempt. At this time, FDA has not made an exemption determination, so sponsors must submit a 510(k).
Special controls require testing and labeling
To be Class II, digital therapy devices for amblyopia must meet special controls including: clinical performance testing (with evaluation of adverse events and measures of visual function); software verification, validation, and hazard analysis with documentation of technical specs; non-clinical performance and compatibility testing of all validated visual displays (resolution, luminance, contrast, field of view, image quality, optical image distance, interpupillary distance); labeling that lists minimum hardware/OS requirements, validated display models, length of treatment/retreatment supported by clinical testing, and a summary of clinical testing; and labeling comprehension testing with intended users.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in